Comparison of Laboratory Findings and Medication Levels according to Antologous Serum Skin Test Reactivity in Chronic Spontaneous Urticaria

Abstract

BACKGROUND
The autologous serum skin test is reported to be positive in up to 60% of patients with chronic spontaneous urticaria. However, the clinical role of autologous serum skin test is still poorly understood.
METHODS
We reviewed the medical records of 166 chronic spontaneous urticaria patients whose symptoms lasted for more than 6 weeks and compared their laboratory findings and medication levels according to autologous serum skin test reactivity.
RESULTS
Autologous serum skin test was positive in 69 (41.6%) chronic spontaneous urticaria patients. There were no significant differences between autologous serum skin test-positive and autologous serum skin test-negative groups in laboratory findings, such as anti-microsome antibody, anti-thyroglobulin antibody, anti-nuclear antibody, total immunoglobulin E, complement 4 level levels, rheumatoid factor, erythrocyte sedimentation rate and D-dimer. Autologous serum skin test were not related to medication levels. Eight patients (11.6%) of autologous serum skin test-positive groups and 6 patients (6.2%) of autologous serum skin test-negative groups need level 4 medication (usage of cyclosporine, dapsone or anti-immunoglobulin E monoclonal antibody) to control urticaria without statistical significance.
CONCLUSION
Autologous serum skin test was positive in more than 40% of chronic spontaneous urticaria patients. However, laboratory findings and medication levels were not affected by autologous serum skin test reactivity.

Comparison of Laboratory Findings and Medication Levels according to Antologous Serum Skin Test Reactivity in Chronic Spontaneous Urticaria

Abstract

MeSH Terms

Cited

Save citations to file

Email citations